Du är här


Weifa ASA: Launches Bronkyl forte 600 mg to drive growth in the Cough & Cold category

Launches Bronkyl forte 600 mg to drive growth in the Cough&Cold category

Weifa ASA is proud to announce the launch of Bronkyl forte 600 mg effervescent
tablets, a new line extension to the already well established Bronkyl 200 mg.
Bronkyl 200 mg is as per today the 6thmost sold OTC product in Norway. The
addition of a new 600 mg line extension is expected to strengthen further the

"Our ambition for the Bronkyl brand is to become market leader within the OTC
cough segment (measured by value
) in Norway. The launch of Bronkyl forte, combined with a strong pipeline, is
another step towards achieving our goal to be the fastest growing company in
the Cough&Cold category in Norway" says CEO Kathrine Gamborg Andreassen in
Weifa ASA.

Bronkyl forte contains acetylcysteine which is a mucolytic agent helping clear
your chest from unwanted mucus. This new 600 mg strength makes it possible to
have a dosage of only one effervescent tablet per day.

From 15 September 2015, Bronkyl forte in 10 tablets package will be available
without prescription in all pharmacies in Norway. The launch will be
supported by a solid communication campaign both towards the end user and the
medical staff.

Further information from:

Kathrine Gamborg Andreassen
+47 95 17 86 80

Simen Nyberg-Hansen
+47 98 20 63 55

Weifa is Norway's leading consumer health company. We supply real value
through medicines, lifestyle products and solutions that address the
essential needs of consumers, customers and professional partners. Weifa was
founded in 1940 and now employs about 30 highly qualified people at our
headquarters in Oslo.
The company has a strong position in Norway and is the market leader in pain
relief, with well-established brands such as Paracet and Ibux. We are also
present in other key areas such as dietary supplements and treatment for
colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker
WEIFA). For further information, please visit:

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Weifa ASA via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.